Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs BlackRock TCP Capital Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.2 (market cap $39.89B), while BlackRock TCP Capital Corp trades at $3.2 (market cap $273.10M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 146.1× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 25.81% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TCPC | |
|---|---|---|
Market Cap | $39.89B | $273.10M |
Sector | Health | Financials |
52-Week High | $491.22 | $7.90 |
52-Week Low | $278.09 | $3.14 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 25.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TCPC trades at $3.26, up 3.16% today, but faces a bearish technical outlook with negative revenue and net income trends. The company reported a net loss of $88.93M for 2025 with revenue of -$77.27M, though it maintains a dividend yield above 10%. Recent news highlights potential dividend sustainability concerns and an ongoing legal investigation into corporate governance.
The outlook remains challenging with declining fundamentals and bearish technical signals. Investment opportunities exist for income-focused investors due to high dividend yield, but risks include persistent losses, legal scrutiny, and negative analyst sentiment with only 30.77% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
